As small business owners shop for 2019 health insurance , some will for the first time have the chance to join forces and buy cheaper insurance -- depending on which state they're in. New rules that began going into effect last month allow sole proprietors and other business owners without employees to form what are known as association health plans, or AHPs. But while the Trump administration has touted the rules as a breakthrough, many owners will be disappointed to learn their states' insurance laws will limit their ability to join the plans. The rules issued by the Labor Department allow sole proprietors and partners to buy coverage that wasn't available to them under the Affordable Care Act. The rules also permit the plans to offer insurance that doesn't meet the health law's requirements for basic coverage. The catch for many businesses is the rules, unlike many other federal laws and regulations, don't supersede state requirements for health insurance, and … [Read more...] about How Small Business Owners Can Team Up to Offer Cheaper Health Insurance
Can foreigners buy health insurance in usa
If you've walked around your local pharmacy recently, you know that at-home coronavirus testing kits are hard to come by. In particular, Abbott Laboratories ( NYSE:ABT ) makes BinaxNOW kits, which are the most popular rapid coronavirus antigen diagnostic test in the U.S. But despite strong sales throughout the pandemic, rapid testing has been a somewhat fickle driver of growth for shareholders. Though Abbott's total return has grown by more than 54% since January of 2020 in comparison to the market's growth of around 49%, its performance in the last 12 months has lagged the market. Are things different this time as a result of the omicron variant wave, or is Abbott on track to disappoint? Image source: Getty Images. Recent testing surges haven't always been enough to outperform the market Coronavirus rapid testing revenue has been all over the place, appearing to ebb and flow based on the public's perceptions about where the pandemic is headed. In the third quarter … [Read more...] about Will Demand for Rapid COVID-19 Tests Help Abbott Laboratories Beat the Market in 2022?
Share to Twitter Share to Linkedin You already hate Martin Shkreli, the bratty former hedge fund manager who raised the price on a drug to treat infections in AIDS patients by 5,000%. Now it’s time to get to know him. I’m not saying you should get to know Shkreli because you’ll like him in the end. You might hate him more. He is very smart, but also callow and possibly sociopathic. (He prefers "iconoclast.") Yet much of what has been written about him this past week is unrecognizable. He’s not a bro or some big time executive but a small player with tons of bluster who took Wall Street’s ideas about drug pricing to their frightening extreme. He became a target for derision not because of what he did but because he was so cartoonishly easy to parody, essentially fouling the cover-up. Other companies have jacked up prices just as much as his firm, Turing, with no consequences other than soaring stock prices. Hillary Clinton’s reforms? It’s unlikely they’d make a … [Read more...] about My Lunch With Shkreli: What We Should Learn From Pharma’s Latest Monster